Haemonetics Stock Shares Outstanding
| HAE Stock | USD 94.40 1.07 1.15% |
Haemonetics fundamentals help investors to digest information that contributes to Haemonetics' financial success or failures. It also enables traders to predict the movement of Haemonetics Stock. The fundamental analysis module provides a way to measure Haemonetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Haemonetics stock.
Haemonetics |
Haemonetics Company Shares Outstanding Analysis
Haemonetics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Haemonetics Shares Outstanding | 50.79 M |
Most of Haemonetics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Haemonetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Haemonetics has 50.79 M of shares currently outstending. This is 71.87% lower than that of the Health Care Equipment & Supplies sector and 40.88% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 91.12% higher than that of the company.
Haemonetics Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.Haemonetics is currently under evaluation in shares outstanding category among related companies.
Haemonetics Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0612 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 5.42 B | ||||
| Shares Outstanding | 50.79 M | ||||
| Shares Owned By Insiders | 0.76 % | ||||
| Shares Owned By Institutions | 99.24 % | ||||
| Number Of Shares Shorted | 2.24 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.59 X | ||||
| Price To Sales | 3.41 X | ||||
| Revenue | 1.17 B | ||||
| Gross Profit | 530.77 M | ||||
| EBITDA | 249.34 M | ||||
| Net Income | 115.4 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 765.89 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 18.57 X | ||||
| Cash Flow From Operations | 273.06 M | ||||
| Short Ratio | 5.08 X | ||||
| Earnings Per Share | 2.46 X | ||||
| Price To Earnings To Growth | 1.63 X | ||||
| Target Price | 105.57 | ||||
| Number Of Employees | 3.03 K | ||||
| Beta | 0.36 | ||||
| Market Capitalization | 4.74 B | ||||
| Total Asset | 1.93 B | ||||
| Retained Earnings | 253.17 M | ||||
| Working Capital | 517.91 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
| Net Asset | 1.93 B |
About Haemonetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Haemonetics Piotroski F Score and Haemonetics Altman Z Score analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.